| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
INSM Stock Overview
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.
Insmed Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.89 |
| 52 Week High | US$34.44 |
| 52 Week Low | US$16.41 |
| Beta | 2.07 |
| 1 Month Change | 13.29% |
| 3 Month Change | -14.63% |
| 1 Year Change | -26.70% |
| 3 Year Change | -16.17% |
| 5 Year Change | 20.96% |
| Change since IPO | -87.34% |
Recent News & Updates
Is Insmed (NASDAQ:INSM) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Shareholder Returns
| INSM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.5% | 0.07% | -2.5% |
| 1Y | -26.7% | -25.1% | -21.2% |
Return vs Industry: INSM underperformed the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: INSM underperformed the US Market which returned -21.2% over the past year.
Price Volatility
| INSM volatility | |
|---|---|
| INSM Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 13.2% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: INSM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: INSM's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 613 | Will Lewis | https://www.insmed.com |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.
Insmed Fundamentals Summary
| INSM fundamental statistics | |
|---|---|
| Market Cap | US$2.50b |
| Earnings (TTM) | -US$437.63m |
| Revenue (TTM) | US$201.35m |
12.4x
P/S Ratio-5.7x
P/E RatioIs INSM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INSM income statement (TTM) | |
|---|---|
| Revenue | US$201.35m |
| Cost of Revenue | US$46.50m |
| Gross Profit | US$154.86m |
| Other Expenses | US$592.49m |
| Earnings | -US$437.63m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.66 |
| Gross Margin | 76.91% |
| Net Profit Margin | -217.35% |
| Debt/Equity Ratio | 653.3% |
How did INSM perform over the long term?
See historical performance and comparisonValuation
Is INSM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INSM?
Other financial metrics that can be useful for relative valuation.
| What is INSM's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$2.50b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 13.3x |
| Enterprise Value/EBITDA | -7.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does INSM's PS Ratio compare to its peers?
| INSM PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.2x | ||
FOLD Amicus Therapeutics | 9.5x | 25.1% | US$3.0b |
PTCT Therapeutics | 5.2x | 10.6% | US$3.0b |
ACAD ACADIA Pharmaceuticals | 4.7x | 27.9% | US$2.3b |
NTRA Natera | 5.3x | 18.3% | US$3.6b |
INSM Insmed | 12.4x | 40.4% | US$2.5b |
Price-To-Sales vs Peers: INSM is expensive based on its Price-To-Sales Ratio (12.4x) compared to the peer average (6.2x).
Price to Earnings Ratio vs Industry
How does INSM's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: INSM is good value based on its Price-To-Sales Ratio (12.4x) compared to the US Biotechs industry average (13.2x)
Price to Sales Ratio vs Fair Ratio
What is INSM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 12.4x |
| Fair PS Ratio | 13.2x |
Price-To-Sales vs Fair Ratio: INSM is good value based on its Price-To-Sales Ratio (12.4x) compared to the estimated Fair Price-To-Sales Ratio (13.2x).
Share Price vs Fair Value
What is the Fair Price of INSM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate INSM's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate INSM's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INSM's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Insmed forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
48.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INSM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: INSM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: INSM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: INSM's revenue (40.4% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: INSM's revenue (40.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INSM's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has Insmed performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-14.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INSM is currently unprofitable.
Growing Profit Margin: INSM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INSM is unprofitable, and losses have increased over the past 5 years at a rate of 14.3% per year.
Accelerating Growth: Unable to compare INSM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INSM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).
Return on Equity
High ROE: INSM has a negative Return on Equity (-365.06%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Insmed's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: INSM's short term assets ($756.1M) exceed its short term liabilities ($125.2M).
Long Term Liabilities: INSM's short term assets ($756.1M) do not cover its long term liabilities ($908.2M).
Debt to Equity History and Analysis
Debt Level: INSM's net debt to equity ratio (123.5%) is considered high.
Reducing Debt: INSM's debt to equity ratio has increased from 45.4% to 653.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INSM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: INSM has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 16.2% each year.
Discover healthy companies
Dividend
What is Insmed current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INSM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INSM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INSM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INSM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as INSM has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.9yrs
Average management tenure
CEO
Will Lewis (53 yo)
9.83yrs
Tenure
US$7,322,642
Compensation
Mr. William H. Lewis, also known as Will, J.D., M.B.A., has been Chief Executive Officer and President at Insmed Incorporated since September 11, 2012 and has been its Chairman of Board since November 6, 2...
CEO Compensation Analysis
Compensation vs Market: Will's total compensation ($USD7.32M) is about average for companies of similar size in the US market ($USD6.91M).
Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: INSM's management team is considered experienced (2.9 years average tenure).
Board Members
Experienced Board: INSM's board of directors are considered experienced (8.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: INSM insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.
Top Shareholders
Company Information
Insmed Incorporated's employee growth, exchange listings and data sources
Key Information
- Name: Insmed Incorporated
- Ticker: INSM
- Exchange: NasdaqGS
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$2.497b
- Shares outstanding: 119.52m
- Website: https://www.insmed.com
Number of Employees
Location
- Insmed Incorporated
- 700 US Highway 202/206
- Bridgewater
- New Jersey
- 8807
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/03 00:00 |
| End of Day Share Price | 2022/07/01 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.